Skip to main content

March 6, 2026

Mofiyin Obadina, MD and Erica Sparkenbaugh, PhD received funding from NC TRaCS

Mofiyin Obadina, MD and Erica Sparkenbaugh, PhD received funding from NC TRaCS for their TTSA proposal entitled “Hypoxemia-Induced Platelet Activation in Sickle Cell Disease Pregnancy: Mechanisms and Therapeutic Targets.” This award supports the development of new interdisciplinary collaborations and projects. Here, Dr. Obadina and Dr. Sparkenbaugh will explore the effect of nocturnal hypoxemia on aberrant …

Photo of Nirupama Ramadas

February 17, 2026

Drs. Nirupama Ramadas and Erica Sparkenbaugh publish in Blood Advances

Dr. Ramadas and Sparkenbaugh recently published their study “Targeting PAR1 Biased Signaling with Parmodulin Reduces Thromboinflammation and Acute Lung Injury in Sickle Cell Disease” in Blood Advances. UNC BRC undergraduate alumni Joshua Dutton and Kailyn Lowder are co-authors. Drs Rani Sellers and Claire Kazen performed veterinary histopathology. Drs. Jacob DeRousse and Chris Dockendorff provided reagents. …

Headshot of Wolfgang bergmeier, PhD

February 12, 2026

Dr. Wolfgang Bergmeier and his lab team are uncovering how platelet dysfunction affects bleeding and clotting in patients

At UNC-Chapel Hill, Dr. Wolfgang Bergmeier and his lab team are uncovering how platelet dysfunction affects bleeding and clotting in patients. Their research is shaping more effective transfusion strategies and new combination therapies to improve patient care. Platelets are the body’s first responders. By studying how platelets function in both health and disease, researchers are …

Dr. Nigel Key

January 2, 2026

Key Lab publishes study describing rapid and sensitive assay for hyperfibrinolysis in plasma

Key Lab publishes study describing rapid and sensitive assay for hyperfibrinolysis in plasma. In collaboration with colleagues in the UK who first described a form of severe post-partum hemorrhage (PPH) characterized by marked hyperfibrinolysis, a novel rapid assay for fibrinolytic activation in plasma developed in the lab (the Fibrinolytic Activation Screening Test or ‘FAST’ assay) reliably distinguished Acute Obstetric …